Biotech | January 22, 2022
Pfizer and OPKO update on the Biologics License Application for Somatrogon
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
_256_384.jpg)
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
Chicago based virtual reality company reaches AIIMS, assisting in surgical planning and training
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Evusheld is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorised in the US to prevent Covid-19
Approximately five kg tumor was removed in the eight-hour long complicated surgery
Subscribe To Our Newsletter & Stay Updated
